NuPharm has rebranded to become Neuraxpharm, in an “exciting new chapter” for the company that “positions Neuraxpharm as a single and differentiated central nervous system (CNS) oriented firm within the European pharmaceutical industry”.
NuPharm has rebranded to become Neuraxpharm, in an “exciting new chapter” for the company that “positions Neuraxpharm as a single and differentiated central nervous system (CNS) oriented firm within the European pharmaceutical industry”.
The group was created in 2016 by combining five companies – Spain’s Qualigen, Laboratorios Lesvi and Inke; Germany’s Neuraxpharm, which...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
